Extending FDA-approved cancer drug indications requires high patient numbers, study finds Post author: Post published:September 29, 2023 Post category:uncategorized Number of patient participants needed for secondary approval of a new cancer drug. You Might Also Like To ban or not to ban, the case for reformulating ultra-processed foods April 1, 2024 Researchers uncover how Bartonella causes deadly Oroya fever December 15, 2025 Innovative AI diabetes training module gets national recognition July 13, 2024